Semax
Semax is a synthetic peptide derived from a fragment of ACTH (4-10) studied in laboratory research for cognitive enhancement and neuroprotection. It is a research compound not approved by the FDA for human use and is utilized exclusively in preclinical investigations.
What is Semax?
Semax is a synthetic peptide developed from a fragment of adrenocorticotropic hormone (ACTH), specifically the 4-10 amino acid sequence, combined with a C-terminal Pro-Gly-Pro tripeptide. Originally synthesized in Russia, Semax was designed to harness neuroprotective and nootropic properties by modulating endogenous neuropeptide systems.
Its mechanism centers on enhancing neuroplasticity through activation of brain-derived neurotrophic factor (BDNF) pathways alongside hepatocyte growth factor (HGF)/c-Met signaling. These pathways are integral to neurogenesis, neuronal survival, and repair processes following neural injury.
Within research contexts, Semax is studied for its potential to improve cognitive function, promote neuroregeneration, and mitigate neuroinflammatory responses. Its biochemical profile includes a molecular formula of C37H51N9O10S and a molecular weight of 813.9 g/mol, with PubChem CID 9811102. Semax remains a research chemical without regulatory approval for clinical use.
Researchers focus on Semax to elucidate mechanisms of neuroprotection and to explore therapeutic avenues for neurological disorders and injury recovery, emphasizing its role in modulating neurotrophic and ubiquitination pathways.
Key Benefits & Mechanisms
- Neuroprotection and Cognitive EnhancementPreclinical studies indicate that Semax supports neuronal survival and enhances cognitive functions by activating neurotrophic factors such as BDNF. This neuroprotective effect is associated with improved synaptic plasticity and memory performance in experimental models.
- Promotion of Neurogenesis and NeuroregenerationSemax has been shown to stimulate neurogenesis and support regeneration of damaged neural tissue. Its activation of HGF/c-Met signaling pathways contributes to cellular repair mechanisms, making it a candidate for studies involving neural injury recovery.
- Modulation of NeuroinflammationResearch suggests Semax can attenuate neuroinflammatory responses by reducing oxidative stress and inhibiting pathways such as lysosomal membrane permeabilization (LMP)-related pyroptosis. This anti-inflammatory effect is particularly relevant in models of spinal cord injury and neurodegenerative conditions.
- Regulation of Ubiquitination ProcessesRecent investigations reveal that Semax influences ubiquitination pathways by modulating enzymes like ubiquitin-specific protease USP18. This regulatory effect may contribute to maintaining lysosomal integrity and promoting functional recovery after neural trauma.
- Potential Applications in Orthopaedic and Neuroimmune ResearchAs part of broader peptide research, Semax is studied alongside other neuroactive peptides for its capacity to enhance brain-derived neurotrophic factor signaling, which may have implications in neuromuscular recovery and neuro-immune interactions, although clinical data are currently lacking.
Mechanism of action
Semax exerts its effects primarily through the enhancement of neuroplasticity by activating brain-derived neurotrophic factor (BDNF) pathways and hepatocyte growth factor (HGF)/c-Met signaling cascades. These pathways are fundamental to neurogenesis, neuronal survival, and the regeneration of neural tissue. Additionally, Semax modulates ubiquitination processes, particularly by influencing ubiquitin-specific protease enzymes such as USP18, which contributes to the maintenance of lysosomal membrane stability and reduces neuronal cell death mechanisms like lysosomal membrane permeabilization (LMP)-induced pyroptosis. This combined action supports neuroprotection and functional recovery in preclinical models of neural injury and cognitive impairment.
Research Summary
Research into Semax encompasses its neuroprotective, cognitive-enhancing, and regenerative properties. The 2026 review "Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions" highlights Semax among neuroactive peptides that enhance BDNF and HGF/c-Met pathways, emphasizing its potential in neuromuscular recovery and neuroplasticity, albeit noting a lack of clinical trials to date.
The 2018 article "Pharmacological Aspects of Neuro-Immune Interactions" discusses the interplay between neurogenesis and immunomodulation, situating Semax within a broader context of psychotropic drugs that influence neuro-immune signaling and suggesting mechanisms for its pleiotropic effects.
In the 2025 study "Semax peptide targets the μ opioid receptor gene Oprm1 to promote deubiquitination and functional recovery after spinal cord injury in female mice," Semax demonstrated the capacity to improve functional recovery post-spinal cord injury by inhibiting lysosomal membrane permeabilization-related pyroptosis. The peptide modulated oxidative stress and regulated ubiquitin-specific protease USP18, with molecular docking implicating interactions with the μ-opioid receptor gene, underscoring complex neuroprotective mechanisms.
- Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions. (2026) PubMed · PMID 41490200
- Pharmacological Aspects of Neuro-Immune Interactions. (2018) PubMed · PMID 28875850
- Semax peptide targets the μ opioid receptor gene Oprm1 to promote deubiquitination and functional recovery after spinal cord injury in female mice. (2025) PubMed · PMID 40692165
Dosing in Research Literature
Published preclinical studies investigating Semax utilize a variety of dosing protocols depending on the experimental model and endpoints. Dosing regimens in animal studies often involve administration via intranasal or parenteral routes at concentrations designed to achieve neuroprotective or cognitive-enhancing effects, though exact dosage ranges vary significantly across studies.
Due to limited standardized data and variability in experimental design, precise dosing parameters for Semax have not been firmly established in the literature. Researchers typically tailor dosing based on the specific model system, duration of treatment, and desired outcomes, emphasizing the compound’s investigational status and the need for further pharmacokinetic and pharmacodynamic characterization.
The figures above describe doses reported in published or preclinical research, provided for context only. This is not medical advice or a dosing recommendation, and these compounds are not approved for human use.
Common Stacks
Frequently asked questions about Semax
Is Semax approved by the FDA for clinical use?
Semax is not approved by the U.S. Food and Drug Administration (FDA) for clinical use. It is classified as a research chemical and is intended solely for laboratory and preclinical research purposes.
What is Semax primarily studied for in research?
Semax is primarily researched for its neuroprotective and cognitive-enhancing properties. Studies focus on its ability to promote neuroplasticity, neurogenesis, and functional recovery in models of neural injury and cognitive impairment.
How does Semax exert its biological effects?
Semax acts by enhancing neuroplasticity through activation of brain-derived neurotrophic factor (BDNF) and hepatocyte growth factor (HGF)/c-Met signaling pathways. It also modulates ubiquitination processes, which contribute to neuronal survival and reduction of neuroinflammation in preclinical models.
Can Semax be combined with other peptides in research?
Yes, Semax is often studied in combination with other peptides such as Selank, which also influences neurotrophic pathways, and BPC-157, known for tissue healing. These combinations are explored to investigate potential synergistic effects on neuroprotection and recovery.
What are the recommended storage and handling conditions for Semax in research?
As a research peptide, Semax should be stored according to manufacturer specifications, typically under refrigerated or frozen conditions to maintain stability. Handling should follow laboratory safety protocols to preserve compound integrity and ensure researcher safety.
Legal & research status: Research use only — not approved by the FDA for human use. Sold and discussed for laboratory and research use only, not for human consumption.